Belmont Capital’s Gilead Sciences GILD Stock Holding History

Belmont Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$408K	Hold	3,684	–	–	0.06%	84
2025 Q1	$413K	Sell	3,684 -5,728	-61%	-$591K	0.07%	80
2024 Q4	$869K	Sell	9,412 -3,000	-24%	-$270K	0.14%	39
2024 Q3	$1.04M	Sell	12,412 -10,900	-47%	-$832K	0.17%	43
2024 Q2	$1.6M	Buy	23,312 +19,628	+533%	+$1.31M	0.3%	29
2024 Q1	$270K	Hold	3,684	–	–	0.07%	79
2023 Q4	$298K	Hold	3,684	–	–	0.13%	66
2023 Q3	$276K	Buy	3,684 +3,362	+1,044%	+$259K	0.15%	57
2023 Q2	$24.8K	Buy	322 +90	+39%	+$7.18K	0.01%	90
2023 Q1	$19.2K	Buy	232 +116	+100%	+$9.61K	0.02%	65
2022 Q4	$10K	Hold	116	–	–	0.01%	97
2022 Q3	$7K	Buy	+116	New	+$7.32K	0.01%	99

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Belmont Capital's GILD Position: Q2 2025 in Review

Belmont Capital held its Gilead Sciences (GILD) position steady in Q2 2025 at 3,684 shares worth $408K. The position accounts for 0.06% of the portfolio, ranked #84.

Belmont Capital first reported a position in GILD in Q3 2022 and has held it in 12 quarters since. The position peaked at $1.6M in Q2 2024. 2,024 funds tracked by Wall St. Rank hold GILD as of Q2 2025.

Belmont Capital held 3,684 shares of Gilead Sciences worth $408K as of Q2 2025.
Belmont Capital left its Gilead Sciences share count unchanged in Q2 2025.
Gilead Sciences made up 0.06% of Belmont Capital's portfolio in Q2 2025, its #84 holding.
Belmont Capital first reported a position in Gilead Sciences in Q3 2022 and has held it in 12 quarters since.
Belmont Capital's Gilead Sciences position peaked at $1.6M in Q2 2024.
2,024 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2025.

Based on Belmont Capital's 13F filing for Q2 2025, filed 12 Aug 2025.